These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 18037408)

  • 1. The c-myc promoter: still MysterY and challenge.
    Wierstra I; Alves J
    Adv Cancer Res; 2008; 99():113-333. PubMed ID: 18037408
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Absence of a paused transcription complex from the c-myc P2 promoter of the translocation chromosome in Burkitt's lymphoma cells: implication for the c-myc P1/P2 promoter shift.
    Strobl LJ; Kohlhuber F; Mautner J; Polack A; Eick D
    Oncogene; 1993 Jun; 8(6):1437-47. PubMed ID: 8502472
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The intron enhancer of the immunoglobulin kappa gene activates c-myc but does not induce the Burkitt-specific promoter shift.
    Polack A; Strobl L; Feederle R; Schweizer M; Koch E; Eick D; Wiegand H; Bornkamm GW
    Oncogene; 1991 Nov; 6(11):2033-40. PubMed ID: 1945409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deregulation of the proto-oncogene c-myc through t(8;22) translocation in Burkitt's lymphoma.
    Gerbitz A; Mautner J; Geltinger C; Hörtnagel K; Christoph B; Asenbauer H; Klobeck G; Polack A; Bornkamm GW
    Oncogene; 1999 Mar; 18(9):1745-53. PubMed ID: 10208435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of immunoglobulin kappa elements in c-myc activation.
    Hörtnagel K; Mautner J; Strobl LJ; Wolf DA; Christoph B; Geltinger C; Polack A
    Oncogene; 1995 Apr; 10(7):1393-401. PubMed ID: 7731690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The block of elongation in c-myc exon 1 is abolished in Burkitt's lymphoma cell lines with variant translocation.
    Eick D; Polack A; Kofler E; Bornkamm GW
    Oncogene; 1988 Oct; 3(4):397-403. PubMed ID: 3078949
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Two regulatory domains are required for downregulation of c-myc transcription in differentiating U937 cells.
    Skerka C; Zipfel PF; Siebenlist U
    Oncogene; 1993 Aug; 8(8):2135-43. PubMed ID: 8336940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Translocations involving c-myc and c-myc function.
    Boxer LM; Dang CV
    Oncogene; 2001 Sep; 20(40):5595-610. PubMed ID: 11607812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Variable IgH chain enhancer activity in Burkitt's lymphomas suggests an additional, direct mechanism of c-myc deregulation.
    Jain VK; Judde JG; Max EE; Magrath IT
    J Immunol; 1993 Jun; 150(12):5418-28. PubMed ID: 8515068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Iron specific growth inhibition of Burkitt's lymphoma cells in vitro, associated with a decrease in translocated c-myc expression.
    Habel ME; Lemieux R; Jung D
    J Cell Physiol; 2005 Apr; 203(1):277-85. PubMed ID: 15468060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional analysis of the N-terminal domain of the Myc oncoprotein.
    Oster SK; Mao DY; Kennedy J; Penn LZ
    Oncogene; 2003 Apr; 22(13):1998-2010. PubMed ID: 12673205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of P0- and P3-RNA from the normal and translocated c-myc allele in Burkitt's lymphoma cells.
    Eick D; Polack A; Kofler E; Lenoir GM; Rickinson AB; Bornkamm GW
    Oncogene; 1990 Sep; 5(9):1397-402. PubMed ID: 2216463
    [TBL] [Abstract][Full Text] [Related]  

  • 13. c-myc Suppression in Burkitt's lymphoma cells.
    Simonsson T; Henriksson M
    Biochem Biophys Res Commun; 2002 Jan; 290(1):11-5. PubMed ID: 11779125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The block to transcription elongation is promoter dependent in normal and Burkitt's lymphoma c-myc alleles.
    Spencer CA; LeStrange RC; Novak U; Hayward WS; Groudine M
    Genes Dev; 1990 Jan; 4(1):75-88. PubMed ID: 2307371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. c-MYC repression of promoter activity through core promoter elements.
    Lucas JM; Wilkie NM; Lang JC
    Biochem Biophys Res Commun; 1993 Aug; 194(3):1446-52. PubMed ID: 8352803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The proto-oncogene c-myc and apoptosis.
    Hoffman B; Liebermann DA
    Oncogene; 1998 Dec; 17(25):3351-7. PubMed ID: 9916997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Translocations among antibody genes in human cancer.
    Leder P
    IARC Sci Publ; 1985; (60):341-57. PubMed ID: 4065947
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in promoter utilization in human and mouse c-myc genes upon transformation induction in temperature-sensitive cell lines.
    Luo Y; Krause MO
    J Cell Physiol; 1994 Aug; 160(2):303-15. PubMed ID: 8040189
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A transcriptional repressor of c-myc.
    Kakkis E; Riggs KJ; Gillespie W; Calame K
    Nature; 1989 Jun; 339(6227):718-21. PubMed ID: 2662014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cell growth inhibition by okadaic acid involves gut-enriched Kruppel-like factor mediated enhanced expression of c-Myc.
    Zhang L; Wali A; Ramana CV; Rishi AK
    Cancer Res; 2007 Nov; 67(21):10198-206. PubMed ID: 17974960
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.